Axial Spondyloarthritis

9
Pipeline Programs
5
Companies
8
Clinical Trials
1 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
4
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 5 programs with unclassified modality

On Market (4)

Approved therapies currently available

UP
BIMZELXApproved
bimekizumab
UCB Pharma
injection2023
UP
CIMZIAApproved
certolizumab pegol
UCB Pharma
Tumor Necrosis Factor Blocker [EPC]injection2008
U
SIMPONIApproved
golimumab
Unknown Company
Tumor Necrosis Factor Blocker [EPC]injection2009
Eli Lilly and Company
TALTZApproved
ixekizumab
Eli Lilly and Company
Interleukin-17A Antagonist [EPC]injection2016

Competitive Landscape

5 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
2 programs
2
1
BimekizumabPhase 3Monoclonal Antibody1 trial
Certolizumab PegolPhase 31 trial
Active Trials
NCT04436640Active Not Recruiting508Est. Aug 2026
NCT02552212Completed317Est. May 2020
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
1
IxekizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT02757352Completed303Est. May 2019
M&
Merck & Co.RAHWAY, NJ
3 programs
1
GolimumabPhase 3Monoclonal Antibody1 trial
MRE review for evidence of axSpA in SIJsN/A1 trial
TreatmentN/A1 trial
Active Trials
NCT03817983Completed259Est. Aug 2020
NCT02011386Completed53Est. Feb 2017
NCT03270501Completed64Est. Dec 2023
XBiotech
XBiotechAUSTIN, TX
1 program
1
NatrunixPhase 21 trial
Active Trials
NCT06526377Not Yet Recruiting60Est. Apr 2027
Novartis
NovartisBASEL, Switzerland
1 program
SmartwatchN/A1 trial
Active Trials
NCT06807853Recruiting50Est. Nov 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
UCB PharmaBimekizumab
Merck & Co.Golimumab
Eli Lilly and CompanyIxekizumab
UCB PharmaCertolizumab Pegol
XBiotechNatrunix
NovartisSmartwatch
Merck & Co.MRE review for evidence of axSpA in SIJs
Merck & Co.Treatment

Clinical Trials (8)

Total enrollment: 1,614 patients across 8 trials

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Start: Jun 2020Est. completion: Aug 2026508 patients
Phase 3Active Not Recruiting

Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation

Start: Nov 2017Est. completion: Dec 202364 patients
Phase 3Completed

A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis

Start: Aug 2016Est. completion: May 2019303 patients
Phase 3Completed
NCT02552212UCB PharmaCertolizumab Pegol

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

Start: Sep 2015Est. completion: May 2020317 patients
Phase 3Completed

Natrunix in HLA-B27 Positive Subjects With Axial Spondyloarthritis

Start: Aug 2026Est. completion: Apr 202760 patients
Phase 2Not Yet Recruiting

A LONGITUDINAL OBSERVATIONAL STUDY to EVALUATE the EFFICACY of MOVEMENT and IMPLEMENT CONCRETE MOVEMENT RECOMMENDATIONS with the HELP of MOBILITY TRACKING with SMARTWATCHES in SUBJECTS with AXIAL SPONDYLOARTHRITIS

Start: Apr 2024Est. completion: Nov 202550 patients
N/ARecruiting
NCT03817983Merck & Co.MRE review for evidence of axSpA in SIJs

MRE as a Screening Tool for axSpA in IBD

Start: Mar 2019Est. completion: Aug 2020259 patients
N/ACompleted

Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis

Start: Feb 2013Est. completion: Feb 201753 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,614 patients
5 companies competing in this space